MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Calcium Modification: It’s All In the Preparation
Exploring the “why, when, where, and how” of calcium modification therapies and techniques.
By Angela McInerney, MD, and Nieves Gonzalo, MD, PhD
Contemporary PCI and Structural Heart
By Rasha Al-Lamee, MD, and Rahul Sharma, MD
Shockwave Initiates All-Female EMPOWER CAD Coronary IVL Study
September 19, 2022—Shockwave Medical, Inc. announced that the company has initiated EMPOWER CAD, a coronary artery disease (CAD) intervention study consisting of all female patients to determine whether the positive results from earlier coronary studies of intravascular lithotripsy (IVL) with the Shockwave C2 coronary IVL catheter (which showed similar safety outcomes across both sexes) can be replicated in an expanded, real-world population of female patients with severely calcified coronary lesions.
Shockwave EMPOWER CAD Evaluates IVL-First Strategy in Female Patients
May 20, 2025—Shockwave Medical, Inc., part of Johnson & Johnson MedTech, announced the 30-day primary endpoint results of the EMPOWER CAD study.
Cordis Initiates SELUTION Global Coronary Registry
May 19, 2025—Cordis announced the initiation of the SELUTION Global Coronary Registry.
Shockwave Launches C2+ IVL Catheter Internationally, Commences All-Female EMPOWER CAD Study
May 15, 2023—Shockwave Medical, Inc. announced the full commercial availability in select international markets of the Shockwave C2+ coronary intravascular lithotripsy (IVL) catheter.
